CA2325541C - Formulations a liberation prolongee de derives d'erythromycine - Google Patents

Formulations a liberation prolongee de derives d'erythromycine Download PDF

Info

Publication number
CA2325541C
CA2325541C CA002325541A CA2325541A CA2325541C CA 2325541 C CA2325541 C CA 2325541C CA 002325541 A CA002325541 A CA 002325541A CA 2325541 A CA2325541 A CA 2325541A CA 2325541 C CA2325541 C CA 2325541C
Authority
CA
Canada
Prior art keywords
extended release
pharmaceutical composition
polymer
release pharmaceutical
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002325541A
Other languages
English (en)
Other versions
CA2325541A1 (fr
Inventor
Laman A. Al-Razzak
Sheri L. Crampton
Linda E. Gustavson
Ho-Wah Hui
Nelly Milman
Susan J. Semla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25681240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2325541(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/838,900 external-priority patent/US6010718A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to CA002358395A priority Critical patent/CA2358395C/fr
Publication of CA2325541A1 publication Critical patent/CA2325541A1/fr
Application granted granted Critical
Publication of CA2325541C publication Critical patent/CA2325541C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002325541A 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine Expired - Fee Related CA2325541C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002358395A CA2358395C (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/838,900 US6010718A (en) 1997-04-11 1997-04-11 Extended release formulations of erythromycin derivatives
US08/838,900 1997-04-11
CA002285266A CA2285266C (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002285266A Division CA2285266C (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002358395A Division CA2358395C (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Publications (2)

Publication Number Publication Date
CA2325541A1 CA2325541A1 (fr) 1998-10-22
CA2325541C true CA2325541C (fr) 2001-10-09

Family

ID=25681240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002325541A Expired - Fee Related CA2325541C (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Country Status (1)

Country Link
CA (1) CA2325541C (fr)

Also Published As

Publication number Publication date
CA2325541A1 (fr) 1998-10-22

Similar Documents

Publication Publication Date Title
CA2285266C (fr) Formulations a liberation prolongee de derives d'erythromycine
US6872407B2 (en) Extended release formulations of erythromycin derivatives
US20050064033A1 (en) Extended release formulations of erythromycin derivatives
WO2004078111A2 (fr) Compositions de minocycline a liberation prolongee et leurs procedes de preparation
CA2325541C (fr) Formulations a liberation prolongee de derives d'erythromycine
CA2358395C (fr) Formulations a liberation prolongee de derives d'erythromycine
AU773863B2 (en) Extended release formulations of erythromycin derivatives
AU2007201031B2 (en) Extended release formulations of erythromycin derivatives
AU2003270948B2 (en) Extended Release Formulations of Erythromycin Derivatives
CA2465698A1 (fr) Formulations a liberation prolongee de derives d'erythromycine
HK1027023B (en) Extended release formulations of clarithromycin
AU2006201001A1 (en) Extended release formulations of erythromycin derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed